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Role of integrin a3b1 in epithelial- 
to-mesenchymal transition
After a variety of stimuli, such as injury, many epithelial cells, 
including renal epithelial cells, undergo the process of epithe-
lial-to-mesenchymal transition (EMT). The most well-studied 
cytokine as an inducer of EMT is transforming growth factor-b 
(TGF-b). TGF-b1 signaling is regulated at multiple levels, begin-
ning with activation of latent TGF-b1 itself, and including binding 
to its receptor (TGF-bR1) and activation of intracellular Smad-
dependent and -independent signaling pathways. Integrins, via 
their engagement with the extracellular matrix (ECM), appear to 
play a substantial role in TGF-b1 action. First, the integrin aVb6 
and its binding to the ECM molecule fibronectin are required 
for activation of latent TGF-b. In addition, global inhibition of 
b1-integrin matrix binding with blocking antibodies prevents 
EMT in mammary cells. Further, the b1 integrin-associated protein 
integrin-linked kinase has also been implicated in EMT. However, 
whether any integrin a-chain associated with b1 is involved in 
EMT is unknown. Recently, Kim et al. found that an immortalized 
a3-null kidney epithelial cell line failed to upregulate the expected 
mesenchymal markers after TGF-b1 stimulation. They extended 
this observation and found defective TGF-b1 responses in primary 
lung epithelial cells selectively missing a3b1. They then used the 
a3-null cell line to explore the mechanisms by which a3b1 influ-
ences cell responses to TGF-b1 and found a previously unrecog-
nized role for a3b1 in TGF-b1 signaling. As summarized in the 
Figure, the essential function of a3b1 appears to depend on the 
presence of surface complexes on epithelial cells, which are com-
posed of a fraction of a3b1, E-cadherin, and TGF-bR1, which 
critically influence the signaling response to TGF-b1. As the Figure 
also shows, the surface complexes of E-cadherin and TGF-bR1 
bring two key transcription factors involved in induction of EMT 
into spatial proximity: b-catenin and receptor Smads. The unique 
function of a3b1 in this context appears to be related to its affin-
ity for E-cadherin, without which E-cadherin–TGF-bR1 complex 
internalization is impaired and this signaling system does not oper-
ate. Thus, a3b1 has a critical role in the initial TGF-b1 signaling 
leading to epithelial-to-mesenchymal transition. (J Cell Biol 2009; 
184: 309–322; doi:10.1083/jcb.200806067)
Juan Oliver
Expression of galectin-1  
is altered in minimal-change 
nephrotic syndrome
Nephrin is an essential structural component of the glomerular 
slit diaphragm (SD), a highly organized intercellular junction that 
constitutes the ultrafiltration barrier of the kidney. Recent stud-
ies have identified two additional nephrin-interacting SD proteins 
(NEPH1 and NEPH2), suggesting that the zipper-like pattern of the 
SD is formed through complex intra- and intermolecular interac-
tions of these proteins. However, the complexity of the SD structure 
suggests that additional SD components remain to be discovered. 
Shimizu et al. identified galectin-1 (Gal-1) as a new component of 
the SD, binding to the ectodomain of nephrin. Using dual-immun-
ofluorescence and confocal microscopy and dual-immunoelectron 
microscopy, the authors found Gal-1 colocalizing with the ectodo-
main of nephrin at the SD in normal human kidney (Figure). By 
immunoprecipitation and surface plasmon resonance, they con-
firmed a direct molecular interaction between Gal-1 and nephrin. 
Moreover, recombinant Gal-1 induced tyrosine phosphorylation 
of the cytoplasmic domain of nephrin and activation of extracel-
lular signal-regulated kinase 1/2 in podocytes. Podocytes were a 
major site of biosynthesis of Gal-1 in the glomerulus, and the nor-
mal expression patterns and levels of Gal-1 were altered in patients 
with minimal-change nephrotic syndrome. Finally, in puromycin 
aminonucleoside−induced rat nephrosis, an apparent reduction in 
the levels of Gal-1 and nephrin around the onset of heavy proteinu-
ria was also revealed. These data present Gal-1 as a new extracellular 
ligand of nephrin localized at the glomerular SD and provide fur-
ther insight into the complex molecular organization, interaction, 
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Model of TGF-b1 signaling. The schematic illustration summarizes the 
influence of a3b1 on TGF-b1 signaling and EMT. 
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Immunohistochemistry of Gal-1 and -3 in human kidney.
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and structure of the SD, which is an active site of intracellular signal-
ing necessary for podocyte function. (Lab Invest 2009; 89: 178–195; 
doi:10.1038/labinvest.2008.125)
Marc De Broe
Early stent thrombosis in patients 
with acute coronary syndromes 
treated with drug-eluting  
and bare-metal stents
A new study by Aoki et al. explores the risks for early throm-
bosis among patients who underwent coronary artery stenting 
in the Acute Catheterization and Urgent Intervention Triage 
Strategy (ACUITY) trial. Patients with moderate- or high-risk 
acute coronary syndrome were randomly assigned to heparin 
plus glycoprotein IIb/IIIa inhibitors (GPI), bivalirudin plus GPI, 
or bivalirudin monotherapy on presentation. Angiography was 
performed in all patients within 72 hours, and patients were then 
managed with percutaneous coronary intervention, coronary 
artery bypass graft surgery, or medical management at the dis-
cretion of the treating physician. Definite stent thrombosis was 
defined as thrombus demonstrated at angiography, and probable 
stent thrombosis was defined as any death not attributed to a non-
cardiac cause or any Q-wave myocardial infarction where stent 
patency was not documented. Chronic kidney disease (CKD) was 
defined as a calculated creatinine clearance of less than 60 ml/
min using the Cockcroft–Gault equation. The randomized anti-
coagulant therapy did not have a significant effect on the risk of 
early stent thrombosis, but 21.3% of the subjects who experienced 
stent thrombosis were insulin-requiring diabetics, whereas only 
8.6% of the group that did not experience stent thrombosis had 
diabetes. Similarly, approximately 30% of the subjects with stent 
thrombosis had CKD, whereas only 16.8% of the subjects with-
out stent thrombosis had CKD. Both CKD and insulin-requiring 
diabetes mellitus were significant predictors of stent thrombosis. 
Both comorbidities retained their independent and significant 
predictive association. Further, when examined on the level of 
individual lesions, increasing baseline hemoglobin was also asso-
ciated with a greater risk of thrombosis.
The most predictive factors for early thrombosis were the pres-
ence of insulin-requiring diabetes and CKD. Although this study 
does not examine whether the risk continues to increase when 
kidney function declines below 60 ml/min or whether the risk is 
much greater in patients with end-stage renal disease, it demon-
strates that on average a patient with CKD has twice the risk of 
early stent thrombosis as compared with one with normal kidney 
function. This underscores the importance of the evaluation of 
all postprocedural chest pain with at least an electrocardiogram. 
Further studies to determine whether this reflects more aggressive 
disease or a failure of less aggressive anticoagulation will be essential 
for crafting definitive treatment strategies. (Circulation 2009; 119: 
687–698; doi:10.1161/CIRCULATIONAHA.108.804203)
Lynda Szczech
Activation of the renal renin–
angiotensin system in USF2 
transgenic mice
Hyperglycemia increases expression of transforming growth factor-b 
(TGF-b), which in turn stimulates extracellular matrix deposition in 
the kidney, contributing to the development of diabetic nephropathy. 
It was previously shown in mesangial cells that the transcription 
factor upstream stimulatory factor 2 (USF2) was upregulated by 
high glucose, bound to an 18-bp sequence in the thrombospon-
din 1 (TSP1) gene promoter, and enhanced high-glucose-induced 
TSP1 expression. As TSP1 is a major regulator of TGF-b activa-
tion, this results in enhanced TGF-b activity. It was also found that 
USF2 transgenic (Tg) mice developed nephropathy characterized 
by albuminuria, glomerular hypertrophy, and increased TGF-b and 
fibronectin accumulation. Induction of type 1 diabetes with strepto-
zotocin in these mice greatly augmented the changes in the kidney. 
These findings suggested that overexpression of USF2 may contrib-
ute to development of diabetic nephropathy. Interestingly, USF2 has 
been shown to regulate renin expression, and many lines of evidence 
indicate that the renin–angiotensin system has a central role in the 
pathogenesis of diabetic nephropathy. Hence, Shi et al. examined the 
effects of USF2 on the regulation of the renin–angiotensin system in 
the kidney and mesangial cells from USF2 (Tg) mice. They found 
that kidneys of USF2 (Tg) mice had increased renin (Figure) and 
angiotensin II levels but that other components of the system, such 
as renin receptor, angiotensinogen, angiotensin-converting enzyme 
(ACE), ACE2, angiotensin type 1a (AT1a) receptor, and AT2 receptor, 
were not altered. Similarly, mesangial cells isolated from USF2 (Tg) 
mice had increased renin and angiotensin II levels. Mesangial cells 
overexpressing USF2 also increased TGF-b production, which was 
blocked by small interfering RNA-mediated renin gene knockdown 
or treatment with enalapril or losartan. Collectively, these results 
suggest that USF2 promotes renal renin expression and stimulates 
angiotensin II generation, leading to activation of the intrarenal 
renin–angiotensin system. In addition, renin-dependent angiotensin 
II generation mediates the effect of USF2 on TGF-b production in 
mesangial cells, which may contribute to the development of neph-
ropathy in USF2 (Tg) mice. (Am J Physiol Renal Physiol 2009; 296: 
F257–F265; doi:10.1152/ajprenal.90493.2008)
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Kidney renin mRNA, protein, and activity increased in USF2 (Tg) mice.
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